04:58 PM EDT, 03/16/2026 (MT Newswires) -- Black Diamond Therapeutics ( BDTX ) reported Q4 loss late Monday of $0.27 per diluted share, narrowing from a loss of $0.28 a year earlier.

Analysts expected a loss of $0.18 in a FactSet poll.

The precision oncology company said cash, cash equivalents, and investments for the quarter ended December 31 were $128.7 million, which is expected to be sufficient to fund operations through H2 of 2028.

Shares fell more than 3.5% in recent after-hours trading.